Profile data is unavailable for this security.
About the company
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2016
- Employees220.00
- LocationI-MabSuite 400, 2440 Research BlvdROCKVILLE 20850United StatesUSA
- Phone+1 (301) 670-2800
- Websitehttps://www.i-mabbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aadi Bioscience Inc | 25.07m | -61.69m | 54.72m | 53.00 | -- | 0.7935 | -- | 2.18 | -2.29 | -2.29 | 0.9285 | 2.80 | 0.2225 | 0.696 | 4.09 | 281,685.40 | -54.75 | -50.25 | -65.27 | -56.15 | 87.39 | -- | -246.06 | -473.97 | 4.54 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| OptiNose Inc | 75.67m | -31.15m | 55.34m | 132.00 | -- | -- | -- | 0.7313 | -0.2216 | -0.2216 | 0.5416 | -0.2725 | 0.6512 | 0.7659 | 2.96 | 573,272.80 | -26.80 | -48.25 | -- | -98.95 | 90.21 | 86.96 | -41.16 | -131.66 | 0.7198 | -1.61 | 1.48 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
| bluebird bio Inc | 53.12m | -300.52m | 58.76m | 375.00 | -- | -- | -- | 1.11 | -1.84 | -1.84 | 0.3039 | -0.0298 | 0.0985 | 2.03 | 4.42 | 141,653.30 | -55.72 | -34.75 | -96.37 | -40.84 | -43.49 | -124.35 | -565.74 | -5,770.41 | 0.3272 | -13.37 | 1.03 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Cellectar Biosciences Inc | 0.00 | -48.74m | 63.28m | 20.00 | -- | 12.33 | -- | -- | -2.51 | -2.51 | 0.00 | 0.3839 | 0.00 | -- | -- | 0.00 | -271.59 | -83.69 | -682.65 | -99.80 | -- | -- | -- | -- | -- | -41.97 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Procaps Group SA | 414.10m | 52.20m | 64.48m | 5.50k | 1.10 | 1.64 | 0.9255 | 0.1557 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Hongchang International Co Ltd | 5.42m | -208.79k | 66.15m | 8.00 | -- | 1.63 | -- | 12.21 | -0.0004 | -0.0004 | 0.0104 | 0.0784 | 0.0991 | 5.50 | 37.20 | -- | -0.2731 | -7.98 | -0.2965 | -10.94 | 4.51 | 11.47 | -2.76 | -64.88 | 4.64 | -- | 0.3169 | -- | 3,289.22 | -- | -42.63 | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 67.19m | 217.00 | -- | 0.4959 | -- | 21.13 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 22.06m | -30.97m | 70.49m | 176.00 | -- | 5.09 | -- | 3.20 | -2.23 | -2.23 | 1.59 | 1.03 | 0.32 | 0.9265 | 2.03 | 125,312.50 | -43.04 | -34.75 | -66.19 | -46.91 | 54.31 | 55.98 | -134.50 | -153.72 | 2.32 | -- | 0.58 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Rockwell Medical Inc | 98.92m | -1.24m | 75.30m | 237.00 | -- | 2.58 | 52.81 | 0.7613 | -0.0496 | -0.0496 | 3.23 | 0.9015 | 1.80 | 14.45 | 10.84 | 417,371.30 | -2.25 | -46.29 | -3.34 | -65.38 | 16.91 | 4.66 | -1.25 | -36.51 | 2.00 | 0.3194 | 0.2654 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
| Journey Medical Corp | 57.77m | -18.34m | 77.87m | 58.00 | -- | 9.92 | -- | 1.35 | -0.9276 | -0.9276 | 2.93 | 0.5271 | 0.889 | 2.16 | 6.19 | 996,051.80 | -28.22 | -- | -76.21 | -- | 57.32 | -- | -31.74 | -- | 1.03 | -13.65 | 0.6582 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 79.27m | 220.00 | -- | 0.3373 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.37m | 35.00 | 391.37 | 348.44 | -- | 35.44 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| Assertio Holdings Inc | 125.76m | -68.49m | 90.57m | 53.00 | -- | 0.6941 | -- | 0.7202 | -0.7212 | -0.7212 | 1.32 | 1.37 | 0.3834 | 0.9052 | 2.34 | 2,372,887.00 | -20.88 | -21.51 | -30.33 | -32.05 | 70.31 | 88.68 | -54.46 | -62.10 | 1.57 | -- | 0.2293 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
Data as of Nov 21 2024. Currency figures normalised to I-Mab's reporting currency: US Dollar USD
17.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HHLR Advisors Ltd.as of 30 Sep 2024 | 6.91m | 8.54% |
| Caligan Partners LPas of 30 Sep 2024 | 3.50m | 4.33% |
| Boothbay Fund Management LLCas of 30 Sep 2024 | 1.42m | 1.75% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Sep 2024 | 566.65k | 0.70% |
| Two Sigma Advisers LPas of 30 Sep 2024 | 499.30k | 0.62% |
| Two Sigma Investments LPas of 30 Sep 2024 | 408.52k | 0.51% |
| Abaris Investment Management AGas of 30 Apr 2024 | 296.00k | 0.37% |
| abrdn, Inc.as of 30 Sep 2024 | 162.58k | 0.20% |
| Garden State Investment Advisory Services LLCas of 30 Sep 2024 | 144.00k | 0.18% |
| Citadel Securities LLCas of 30 Sep 2024 | 98.39k | 0.12% |
More ▼
Data from 30 Apr 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
